Of manufacturers planning to add production capacity over the next five years for goods consumed in the U.S., more plan to add that capacity in the U.S. than in any other country - a sharp reversal since as recently as two years ago. And a rising percentage of U.S.-based executives at the manufacturers say they are already in the process of reshoring production work from China. These are among the findings of new research released today by The Boston Consulting Group.

As the pace of business accelerates and competition intensifies, companies in virtually all industries are confronting greater uncertainty and complexity. In the face of such challenges, HR has the potential to be a significant strategic asset by ensuring that companies have the human capital they need to compete and the ability to react fast to changing environments.

The growth rate of the large and diverse chemical industry in North America tends to track GDP, but a confluence of factors is expected to accelerate the industry's growth relative to the overall economy during the next five to ten years. By the end of this period, the U.S. - representing more than 80 percent of the North American chemical market - will be a larger net exporter of chemicals than it is today.

Over the last several years, the biopharmaceutical industry worldwide has intensified its focus on quality in manufacturing - but with little to show for it. Manufacturing quality levels remain well below those in other industries, such as semiconductor manufacturing and aerospace. And major recalls are still all too common.

Following the Panama Canal expansion in 2016, up to 10 percent of container traffic to the U.S. from East Asia could shift from West Coast ports to East Coast ports by 2020, according to research conducted by the Boston Consulting Group and C.H. Robinson. Rerouting that volume is equivalent to building a port roughly double the size of the ports in Savannah and Charleston.